Business
PRTC Presents LYT-100 Ph1 PK & Tolerability at ERS
PRTC Presents LYT-100 Ph1 PK & Tolerability at ERS.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3855J\n PureTech Health PLC\n 23 August 2021\n \n \n \n \n 23 August 2021\n \n \n \n \n \n PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021 \n \n \n \n \n \n LYT-100 was well-tolerated when given twice-daily over multiple ascending doses with no maximum tolerated dose observed\n \n \n \n \n \n Results demonstrated dose-proportional PK profile and a modest food effect\n \n \n \n \n \n \n LYT-100 is currently being evaluated in two Phase 2 trials \n \n \n in patients with Long COVID respiratory complications or breast cancer-related, upper limb secondary lymphedema, and planning is underway to potentially evaluate LYT-100\n \n \n in IPF\n \n \n \n \n \n \n PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a\n clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the presentation of the Phase 1 multiple ascending dose and food effect study of LYT-100 at the virtual European Respiratory Society International Congress. LYT-100 is the lead therapeutic candidate from within PureTech's Wholly Owned Pipeline, and it is being advanced for the potential treatment of conditions involving inflammation and fibrosis and disorders of lymphatic flow.\n \n \n \n \n \n \"These data further support the favorable tolerability profile of LYT-100 and have helped inform both our ongoing Phase 2 trials as well as potential future trials in additional indications, including idiopathic pulmonary fibrosis,\" said Michael Chen, PhD, Head of Innovation at PureTech. \"LYT-100 is a deuterated form of pirfenidone, which retains the beneficial pharmacology of pirfenidone and also appears to have a favorable tolerability profile based on the preclinical and clinical data generated thus far. We believe this molecule has the potential to overcome the GI adverse events associated with the current standards of care and become the frontline treatment for patients with interstitial lung disease.\" \n \n \n \n \n \n Multiple ascending dose and food effect study results\n \n \n The Phase 1 multiple ascending dose food and effect study was a randomized, double-blind, placebo-controlled study of...